Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 1.00 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 1.00 |
| ▸ | SENP8 | Q96LD8 | 3/20 | 1.00 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 1.00 |
| ▸ | APAF1 | O14727 | 2/20 | 1.00 |
| ▸ | NSD2 | O96028 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | TDP2 | O95551 | 1/20 | 0.64 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.64 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.64 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | IGFBP3 | P17936 | 2/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29412940 | 1.00 | CASP3 (1.00) | CASP3SENP6SENP8SENP7APAF1 | |
| SCHEMBL194997 | 0.91 | CASP3 (0.83) | CASP3SENP6SENP8SENP7APAF1 | |
| SCHEMBL21690572 | 0.88 | CASP3 (0.79) | CASP3SENP6SENP8SENP7APAF1 | |
| SCHEMBL23457757 | 0.88 | CASP3 (0.78) | CASP3SENP6SENP8SENP7APAF1 | |
| SCHEMBL23458028 | 0.88 | CASP3 (0.78) | CASP3SENP6SENP8SENP7APAF1 | |
| SCHEMBL21690569 | 0.87 | CASP3 (0.77) | CASP3SENP6SENP8SENP7APAF1 | |
| SCHEMBL23458036 | 0.86 | CASP3 (0.76) | CASP3SENP6SENP8SENP7APAF1 | |
| SCHEMBL23457440 | 0.85 | CASP3 (0.74) | CASP3SENP6SENP8SENP7APAF1 | |
| SCHEMBL2463171 | 0.83 | CASP3 (0.71) | CASP3SENP6SENP8SENP7APAF1 | |
| SCHEMBL21690825 | 0.83 | CASP3 (0.70) | CASP3SENP6SENP8SENP7APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4229639-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS Global Biopharma, Inc. (CA) | 2023-08-23 | — | — | EP | claimed |
| WO-2022081889-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS GLOBAL BIOPHARMA, INC. (CA) | 2022-04-21 | — | — | WO | claimed |
| US-20160184232-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.) | 2016-06-30 | — | — | US | claimed |
| CN-103402499-A | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans | MALLINCKRODT LLC | 2013-11-20 | — | — | CN | claimed |
| EP-2654727-A1 | METHODS OF PRODUCING STABILIZED SOLID DOSAGE PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS | Mallinckrodt LLC (US) | 2013-10-30 | — | — | EP | claimed |
| US-20130273153-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2013-10-17 | — | — | US | claimed |
| WO-2012087377-A1 | METHODS OF PRODUCING STABILIZED SOLID DOSAGE PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS | MALLINCKRODT LLC (US) | 2012-06-28 | — | — | WO | claimed |
| US-20110287095-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | Mallinkckrodt Inc. (US) | 2011-11-24 | — | — | US | claimed |
| WO-2011087765-A2 | METHODS OF PRODUCING STABILIZED SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS | MALLINCKRODT INC. (US) | 2011-07-21 | — | — | WO | claimed |
| US-20110150989-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | Mallinkckrodt Inc. (US) | 2011-06-23 | — | — | US | claimed |
| WO-2011041470-A2 | SUSTAINED-RELEASE OPIATE AND OPIATE DERIVATIVE COMPOSITIONS | MALLINCKRODT INC. (US) | 2011-04-07 | — | — | WO | claimed |
| US-20110077222-A1 | Sustained-Release Opiate and Opiate Derivative Compositions | MALLINCKRODT INC. (US) | 2011-03-31 | — | — | US | claimed |
| JP-63310813-A | — | — | None | — | — | JP | disclosed |
| CN-119684549-A | Covalent organic framework material solid-phase microextraction fiber and application thereof in alkaloid metabolism and neurotransmitter analysis | 河南中医药大学 | 2025-03-25 | — | — | CN | disclosed |
| EP-4229639-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS Global Biopharma, Inc. (CA) | 2023-08-23 | — | — | EP | disclosed |
| US-20220130493-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS GLOBAL BIOPHARMA, INC. (CA) | 2022-04-28 | — | — | US | disclosed |
| US-4757124-A | Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-12 | — | — | US | disclosed |
| CN-85107531-A | Process for producing vinyl chloride polymer | — | 1987-01-21 | — | — | CN | disclosed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | disclosed |
| US-4018927-A | Treatment of proliferating skin diseases with papaverine alkaloids | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150989-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | CASP3 2942/4885SENP6 1681/4885SENP8 1190/4885 |
| US-20110287095-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | CASP3 2942/4885SENP6 1681/4885SENP8 1190/4885 |
| US-20110077222-A1 | Sustained-Release Opiate and Opiate Derivative Compositions | OPRL1, OPRK1, OPRM1 | CASP3 4726/4885SENP6 351/4885SENP8 1044/4885 |
| US-20130273153-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | CASP3 2942/4885SENP6 1681/4885SENP8 1190/4885 |
| US-20160184232-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | CASP3 2942/4885SENP6 1681/4885SENP8 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.